Cantitate/Preț
Produs
Total produse
Vezi coșul
Digital Therapeutics: Strategic, Scientific, Developmental, and Regulatory Aspects de Oleksandr Sverdlov

Digital Therapeutics: Strategic, Scientific, Developmental, and Regulatory Aspects: Chapman & Hall/CRC Biostatistics Series

Editat de Oleksandr Sverdlov, Joris van Dam
en Limba Engleză Hardback – 6 dec 2022
One of the hallmarks of the 21st century medicine is the emergence of digital therapeutics (DTx)—evidence-based, clinically validated digital technologies to prevent, diagnose, treat, and manage various diseases and medical conditions. DTx solutions have been gaining interest from patients, investors, healthcare providers, health authorities, and other stakeholders because of the potential of DTx to deliver equitable, massively scalable, personalized and transformative treatments for different unmet medical needs.
Digital Therapeutics: Scientific, Statistical, Clinical, and Regulatory Aspects is an unparalleled summary of the current scientific, statistical, developmental, and regulatory aspects of DTx which is poised to become the fastest growing area of the biopharmaceutical and digital medicine product development. This edited volume intends to provide a systematic exposition to digital therapeutics through 19 peer-reviewed chapters written by subject matter experts in this emerging field.
This edited volume is an invaluable resource for business leaders and researchers working in public health, healthcare, digital health, information technology, and biopharmaceutical industries. It will be also useful for regulatory scientists involved in the review of DTx products, and for faculty and students involved in an interdisciplinary research on digital health and digital medicine.
Key Features:
  • Provides the taxonomy of the concepts and a navigation tool for the field of DTx.
  • Covers important strategic aspects of the DTx industry, thereby helping investors, developers, and regulators gain a better appreciation of the potential value of DTx.
  • Expounds on many existing and emerging state-of-the art scientific and technological tools, as well as data privacy, ethical and regulatory considerations for DTx product development.
  • Presents several case studies of successful development of some of the most remarkable DTx products.
  • Provides some perspectives and forward-looking statements on the future of digital medicine.
Citește tot Restrânge

Din seria Chapman & Hall/CRC Biostatistics Series

  • 9% Controlled Epidemiological Studies
    Preț: 80131 lei
  • 9% Statistical Methods for Dynamic Disease Screening and Spatio-Temporal Disease Surveillance
    Preț: 64331 lei
  • 9% Bayesian Precision Medicine
    Preț: 64304 lei
  • Joint Models for Longitudinal and Time-to-Event Data: With Applications in R
    Preț: 34142 lei
  • Bayesian Analysis with R for Drug Development: Concepts, Algorithms, and Case Studies
    Preț: 31141 lei
  • 8% Statistical Thinking in Clinical Trials
    Preț: 37664 lei
  • Bayesian Adaptive Methods for Clinical Trials
    Preț: 35065 lei
  • 5% Biostatistics for Bioassay
    Preț: 65706 lei
  • Applied Meta-Analysis with R and Stata
    Preț: 35663 lei
  • Real-World Evidence in a Patient-Centric Digital Era
    Preț: 34837 lei
  • Sample Size Calculations in Clinical Research
    Preț: 31141 lei
  • 9% Estimands, Estimators and Sensitivity Analysis in Clinical Trials
    Preț: 72920 lei
  • Interface between Regulation and Statistics in Drug Development
    Preț: 35448 lei
  • Confidence Intervals for Discrete Data in Clinical Research
    Preț: 35903 lei
  • Structural Equation Modeling for Health and Medicine
    Preț: 34289 lei
  • Real-World Evidence in Drug Development and Evaluation
    Preț: 35477 lei
  • Medical Risk Prediction Models: With Ties to Machine Learning
    Preț: 38662 lei
  • 9% Causal Inference in Pharmaceutical Statistics
    Preț: 64152 lei
  • 5% Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials
    Preț: 33101 lei
  • Cure Models: Methods, Applications, and Implementation
    Preț: 28880 lei
  • 5% Statistical Methods in Health Disparity Research
    Preț: 66954 lei
  • Bayesian Methods in Pharmaceutical Research
    Preț: 36200 lei
  • 9% Value of Information for Healthcare Decision-Making
    Preț: 73199 lei
  • 9% ROC Analysis for Classification and Prediction in Practice
    Preț: 64457 lei
  • Signal Detection for Medical Scientists: Likelihood Ratio Test-based Methodology
    Preț: 35663 lei
  • 9% Innovative Methods for Rare Disease Drug Development
    Preț: 83328 lei
  • 9% Quantitative Methods for Precision Medicine: Pharmacogenomics in Action
    Preț: 60832 lei
  • Single-Arm Phase II Survival Trial Design
    Preț: 35722 lei
  • 9% Statistical Design, Monitoring, and Analysis of Clinical Trials: Principles and Methods
    Preț: 59430 lei
  • 9% Analysis of Incidence Rates
    Preț: 94038 lei
  • 18% Design and Analysis of Clinical Trials for Predictive Medicine
    Preț: 77513 lei
  • 18% Bayesian Methods in Health Economics
    Preț: 69228 lei
  • 18% Medical Biostatistics
    Preț: 169518 lei
  • 26% Dose Finding by the Continual Reassessment Method
    Preț: 87378 lei
  • 18% Design and Analysis of Bridging Studies
    Preț: 76971 lei
  • 25% Statistics In the Pharmaceutical Industry
    Preț: 82434 lei
  • 15% Fundamental Concepts for New Clinical Trialists
    Preț: 66442 lei
  • 25% Statistical Methods for Drug Safety
    Preț: 55671 lei
  • 26% Randomization, Masking, and Allocation Concealment
    Preț: 62487 lei
  • 18% Quantitative Methods for HIV/AIDS Research
    Preț: 77045 lei
  • 25% Design and Analysis of Bioavailability and Bioequivalence Studies
    Preț: 77686 lei
  • 25% Exposure-Response Modeling: Methods and Practical Implementation
    Preț: 62732 lei
  • 18% Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects
    Preț: 110217 lei
  • 25% Handbook of Regression and Modeling: Applications for the Clinical and Pharmaceutical Industries
    Preț: 88618 lei
  • 25% Randomized Phase II Cancer Clinical Trials
    Preț: 52599 lei

Preț: 126575 lei

Preț vechi: 154361 lei
-18% Nou

Puncte Express: 1899
Preț estimativ în valută:
24224€ • 25162$ • 20121£

Carte tipărită la comandă

Livrare economică 01-15 februarie 25

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780367861599
ISBN-10: 0367861593
Pagini: 462
Ilustrații: 17 Tables, black and white; 48 Line drawings, color; 57 Halftones, black and white; 105 Illustrations, color
Dimensiuni: 178 x 254 x 25 mm
Greutate: 1.01 kg
Ediția:1
Editura: CRC Press
Colecția Chapman and Hall/CRC
Seria Chapman & Hall/CRC Biostatistics Series

Public țintă

Professional

Cuprins

1. Digital Therapeutics within the Digital Health Landscape: Foundational Aspects. 2. Sector Perspective: Digital Therapeutics in Behavioral Health. 3. Navigating the Code to Commercial Lifecycle of Digital Health Apps: Defining and Defending Your Strategy for Success. 4. Designing and Delivering a DTx Clinical Research Program: No Need to Re-invent the Wheel. 5. Statistical Designs for Developing Personalized Mobile Treatment Interventions. 6. Statistical Approaches in the Development of Digital Therapeutics. 7. Health Economics Aspects of Digital Therapeutics. 8. Healthcare Data Ownership and Privacy: A Perspective for Digital Therapeutics. 9. Building the Story of Scientific Evidence for Digital Therapeutics: Trials, Meta-Analysis, and Real-World Data. 10. U.S. Regulatory Pathways for Digital Therapeutics. 11. Building Digital Health and Therapeutic Solutions for the Future: What's Required for Success? 12. Digital Therapeutics for Sleep and Mental Health. 13. DTx for the NEXT Three Billion! 14. Akili: A Novel Approach to Clinical Intervention with Digital Therapeutics. 15. SilverCloud Health: Online Mental Health and Wellbeing Platform. 16. Digitally Augmenting Therapies: A DTx Opportunity for Pharma Portfolio Development. 17. The Converegence of Digital Health Technologies: The Role of Digital Therapeutics in the Future Healthcare System. 18. Decentralized Clinical Trials: A New Paradigm for New Medical Product Development and Digital Therapeutics. 19. The Past, Present, and Future of Digital Therapeutics. Index.

Notă biografică

Dr. Oleksandr Sverdlov is Neuroscience Disease Area Lead Statistician in early clinical development at Novartis. He received B.Sc. in Applied Mathematics from V.N. Karazin Kharkiv National University, Ukraine, M.Sc. in Statistics from University of Maryland, Baltimore County (UMBC), and Ph.D. in Information Technology with Concentration in Statistical Science from George Mason University. He has been actively involved in methodological research and applications of innovative statistical approaches in drug development. He is the editor of a monograph "Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects" (CRC Press/Chapman & Hall, 2015) and a co-author of a book "Mathematical and Statistical Skills in the Biopharmaceutical Industry: A Pragmatic Approach" (CRC Press/Chapman & Hall, 2019). His most recent work involves design and analysis of proof-of-endpoint clinical studies evaluating novel digital technologies.
Joris van Dam is a Digital Health Intrapreneur, helping organizations deliver upon the promise of digital health technologies to transform the experience and treatment outcomes of the patients we collectively serve. For the past several years, Joris has led the Digital Therapeutics research program at the Novartis Institutes of Biomedical Research in Cambridge, MA. In the 10+ years before that, Joris worked on a wide variety of Digital Health solutions improving the clinical treatment and the clinical research experience of patients and providers in the U.S., Europe, India, and Africa. Joris received a Ph.D. in Computer Science / Artificial Intelligence from the University of Amsterdam in 1998, after which he spent several years in consulting and program management before recognizing the promise and the urgency of digital health solutions to improve the health of our nations.

Descriere

Digital Therapeutics: Scientific, Statistical, Clinical, and Regulatory Aspects is an unparalleled summary of the current scientific, statistical, developmental, and regulatory aspects of DTx which is poised to become the fastest growing area of the biopharmaceutical and digital medicine product development.